PFE Stock Overview
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 2/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 5/6 |
Pfizer Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$28.91 |
| 52 Week High | US$54.93 |
| 52 Week Low | US$28.30 |
| Beta | 0.58 |
| 1 Month Change | -5.24% |
| 3 Month Change | -19.20% |
| 1 Year Change | -43.21% |
| 3 Year Change | -28.33% |
| 5 Year Change | -34.18% |
| Change since IPO | 877.24% |
Recent News & Updates
Pfizer: Disastrous 2023 Hits New Low With Weight Loss Drug Failure
Dec 01Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips
Nov 21High-Quality Dividend Growth Near 52-Week Lows: Pfizer Is Phenomenal
Nov 12Recent updates
Pfizer: Disastrous 2023 Hits New Low With Weight Loss Drug Failure
Dec 01Pfizer Is A Fantastic Buy And So Are These 9%-Yielding Blue Chips
Nov 21High-Quality Dividend Growth Near 52-Week Lows: Pfizer Is Phenomenal
Nov 12Pfizer (NYSE:PFE) Will Pay A Dividend Of $0.41
Nov 05
Pfizer: Value Investment Opportunity After Recent Price Decline
Nov 02Pfizer Stock: Interesting, If Discipline Returns
Oct 23Pfizer's (NYSE:PFE) Dividend Will Be $0.41
Oct 22Downgrade: Here's How Analysts See Pfizer Inc. (NYSE:PFE) Performing In The Near Term
Oct 16Pfizer: Buy This Big Pharma Stock For Safe Income And Deep Value
Oct 15Pfizer (NYSE:PFE) Has Affirmed Its Dividend Of $0.41
Oct 08Is Pfizer (NYSE:PFE) Using Too Much Debt?
Oct 04Pfizer: Protracted Selloff Makes This Best Time To Buy For A Decade
Sep 25Pfizer: The Floor To This Decline Remains To Be Seen
Sep 02Pfizer: Searching For A Bottom
Aug 24Pfizer Stock: The Right Time To Buy Now (Technical Analysis)
Aug 17Pfizer's Unexpected Strength: Bullish Case Emerges Amid New Covid-19 Wave
Aug 11Shareholder Returns
| PFE | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -5.2% | 0.5% | 0.5% |
| 1Y | -43.2% | -4.0% | 11.0% |
Return vs Industry: PFE underperformed the US Pharmaceuticals industry which returned -4% over the past year.
Return vs Market: PFE underperformed the US Market which returned 11% over the past year.
Price Volatility
| PFE volatility | |
|---|---|
| PFE Average Weekly Movement | 3.7% |
| Pharmaceuticals Industry Average Movement | 10.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 15.4% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: PFE is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.
Volatility Over Time: PFE's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1849 | 83,000 | Albert Bourla | https://www.pfizer.com |
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women’s health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Retacrit, Lorbrena, and Braftovi brands.
Pfizer Inc. Fundamentals Summary
| PFE fundamental statistics | |
|---|---|
| Market Cap | US$172.05b |
| Earnings (TTM) | US$10.47b |
| Revenue (TTM) | US$68.54b |
15.6x
P/E Ratio2.4x
P/S RatioIs PFE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PFE income statement (TTM) | |
|---|---|
| Revenue | US$68.54b |
| Cost of Revenue | US$31.10b |
| Gross Profit | US$37.44b |
| Other Expenses | US$26.97b |
| Earnings | US$10.47b |
Last Reported Earnings
Oct 01, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.85 |
| Gross Margin | 54.63% |
| Net Profit Margin | 15.28% |
| Debt/Equity Ratio | 66.0% |
How did PFE perform over the long term?
See historical performance and comparison